United Therapeutics Co. (NASDAQ:UTHR) Shares Sold by Livforsakringsbolaget Skandia Omsesidigt

Livforsakringsbolaget Skandia Omsesidigt cut its stake in shares of United Therapeutics Co. (NASDAQ:UTHR - Free Report) by 25.3% in the 1st quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 21,000 shares of the biotechnology company's stock after selling 7,100 shares during the quarter. Livforsakringsbolaget Skandia Omsesidigt's holdings in United Therapeutics were worth $6,468,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other large investors have also recently made changes to their positions in the company. Newbridge Financial Services Group Inc. purchased a new stake in shares of United Therapeutics in the 4th quarter worth about $25,000. Dunhill Financial LLC increased its position in shares of United Therapeutics by 100.0% during the 4th quarter. Dunhill Financial LLC now owns 100 shares of the biotechnology company's stock valued at $35,000 after purchasing an additional 50 shares during the last quarter. State of Wyoming purchased a new stake in United Therapeutics in the 4th quarter worth approximately $62,000. Millstone Evans Group LLC bought a new stake in United Therapeutics during the 4th quarter worth approximately $67,000. Finally, Curat Global LLC bought a new stake in United Therapeutics during the 1st quarter worth approximately $63,000. 94.08% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

A number of research firms recently weighed in on UTHR. Cantor Fitzgerald assumed coverage on shares of United Therapeutics in a report on Monday, June 2nd. They issued an "overweight" rating and a $405.00 target price for the company. Wells Fargo & Company restated an "equal weight" rating and set a $314.00 price target (down previously from $395.00) on shares of United Therapeutics in a research note on Friday, April 25th. JPMorgan Chase & Co. dropped their price target on United Therapeutics from $355.00 to $350.00 and set an "overweight" rating on the stock in a research note on Thursday, May 1st. Bank of America decreased their target price on United Therapeutics from $321.00 to $315.00 and set a "neutral" rating for the company in a report on Wednesday. Finally, Wall Street Zen downgraded United Therapeutics from a "strong-buy" rating to a "buy" rating in a report on Friday, May 2nd. Four investment analysts have rated the stock with a hold rating and ten have given a buy rating to the company. According to data from MarketBeat.com, the company presently has an average rating of "Moderate Buy" and an average price target of $393.08.

Insider Activity at United Therapeutics

In related news, Director Tommy G. Thompson sold 2,500 shares of United Therapeutics stock in a transaction that occurred on Monday, March 24th. The stock was sold at an average price of $318.80, for a total value of $797,000.00. Following the sale, the director now directly owns 8,480 shares in the company, valued at $2,703,424. The trade was a 22.77% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CFO James Edgemond sold 12,000 shares of United Therapeutics stock in a transaction on Monday, June 9th. The stock was sold at an average price of $325.37, for a total value of $3,904,440.00. Following the transaction, the chief financial officer now directly owns 8,118 shares of the company's stock, valued at approximately $2,641,353.66. This represents a 59.65% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 68,500 shares of company stock worth $20,828,390 over the last three months. 10.30% of the stock is currently owned by corporate insiders.

United Therapeutics Price Performance

Shares of UTHR stock traded down $2.79 during midday trading on Friday, hitting $283.35. The company had a trading volume of 564,424 shares, compared to its average volume of 452,608. The company's 50 day simple moving average is $300.50 and its 200 day simple moving average is $330.86. United Therapeutics Co. has a 52-week low of $266.98 and a 52-week high of $417.82. The stock has a market cap of $12.78 billion, a price-to-earnings ratio of 12.44, a PEG ratio of 0.97 and a beta of 0.57.

United Therapeutics (NASDAQ:UTHR - Get Free Report) last announced its earnings results on Wednesday, April 30th. The biotechnology company reported $6.63 earnings per share for the quarter, beating the consensus estimate of $6.29 by $0.34. United Therapeutics had a return on equity of 19.22% and a net margin of 40.31%. The company had revenue of $794.40 million for the quarter, compared to the consensus estimate of $726.82 million. During the same period last year, the business posted $6.17 EPS. The company's revenue was up 17.2% on a year-over-year basis. Analysts anticipate that United Therapeutics Co. will post 24.48 EPS for the current year.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.